MedTrace Logo

Evaluating the Immune Response for COVID-19

NCT04348422 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 214

Last updated 2026-04-21

No results posted yet for this study

Summary

The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic. The measures in which public health officials quarantine confirmed and isolate symptomatic cases in order to reduce the spread COVID-19 is the common practice used in most countries. However, a significant question remains in regards to the asymptomatically infected individuals, which may propagate the virus and impede infection control. The other question to consider is whether these asymptomatic carriers develop an immune response or continue viral shedding. The purpose of the current study is the evaluate the immune response, i.e developing anti-SARS-CoV-2 antibodies in the asymptomatic cases, in a household study design.

We plan to evaluate over 1000 patients with positive COVID-19 results and their households.

Conditions

Interventions

DIAGNOSTIC_TEST

COVID-19 RT-PCR

Nasoropharyngeal swabs for COVID-19 RT-PCR - initial screening/retest +every 10 days in 100 days followup period

DIAGNOSTIC_TEST

COVID-19 Serology

Blood samples for COVID-19 serology - initial screening/retest +every 10 days in 100 days followup period Each sample will be examined by 4-6 serology kits.

OTHER

Symptoms questionnare

Symptoms questionnaire which will be filled by participant on initial screening/retest visit + every 10 days in 100 days followup period

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • Shai Efrati, MD · Head of Research and Development Unit

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2022-02-02
Completion
2022-02-02

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04348422 on ClinicalTrials.gov